SDDS 2021 - Posters - San Diego Dermatology Symposium

2021 POSTERS

Back to Symposium Archives

#101 - Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Mark Lebwohl, MD, Linda Stein Gold, MD, Bruce Strober, MD, Kim Papp, MD, PhD, April Armstrong, MD, Jerry Bagel, MD, Leon Kircik, MD, Benjamin Ehst, MD, PhD, H. Chih-ho Hong, MD, Jennifer Soung, MD, Jeff Fromowitz, MD, Scott Guenthner, MD, Stephen C. Piscitelli, PharmD, David S. Rubenstein, MD, PhD, Philip M. Brown, MD, JD, Anna M. Tallman, PharmD, Robert Bissonnette, MD

Full COI

#102 - Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Interim Analysis of a Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Bruce Strober, MD, Robert Bissonnette, MD, April Armstrong, MD, Linda Stein Gold, MD, Andrew Blauvelt, MD, MBA, Leon Kircik, MD, Philip M. Brown, MD, Anna M. Tallman, PharmD, Mark Lebwohl, MD

Full COI

#103 - Molecular pathogenesis and Complications Associated with Keratosis Follicularis

Hira Ghani, BA, Marielle Jamgochian, MS, Amy Pappert, MD, Raphia Rahman, MBS,
Stefanie Cubelli, DO

#104 - Case Report and Literature Review on Parry-Romberg Syndrome Presenting Later in Life

Hira Ghani, BA, Stefanie Cubelli, DO, Jordan Fabrikant, DO, Raphia Rahman, MBS

#105 - Progressive and sustained improvements in extent and severity of atopic dermatitis in patients with moderate-to-severe disease treated with tralokinumab plus topical corticosteroids as needed

Andrew F. Alexis, MD, Matthew Zirwas, Andreas Pinter, David N. Adam, Andrea Chiricozzi, Andrew E. Pink, Thomas Mark, Ann-Marie Tindberg, Jonathan I. Silverberg, MD

#106 - Early and sustained improvements in patient-reported outcomes with tralokinumab plus topical corticosteroids in moderate-to-severe atopic dermatitis

Boni E. Elewski, Sonja Ständer, Matthew Zirwas, Juan Francisco Silvestre, Sunil Kalia, Jan Gutermuth, Thomas Mark, Ann-Marie Tindberg, Jonathan I. Silverberg, MD

#107 - Tralokinumab provides progressive improvements beyond week 16 in patients with atopic dermatitis who have an initial partial response

Eric Simpson, MD, Jacob P Thyssen, Carsten Flohr, Norito Katoh, Kim Papp, Louise Abildgaard Steffensen, Bo Bang, Alexandra Kuznetsova, Andrew Blauvelt

#108 - Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled trials

Eric Simpson, MD, Joseph F Merola, Jonathan I Silverberg, Rebecca Zachariae, Christina Kurre Olsen, Andreas Wollenberg

#109 - The safety of rituximab for the treatment of autoimmune blistering diseases: a systematic review

Arooj Mohammed BS, Daniel Hekman MD, Wendy Li MD, Chelsea Misquith MI, Sahand Rahnama-Moghadam MD, MS.

#110 - Unicentric Castleman Disease in the Temporal Region of a Pediatric Patient

Samantha Haraszti, DO, Jeffrey Dickman, DO, Karen Warschaw, MD, Weimin Hu, MD

#111 - CK20-Positive CK7-Negative Metastatic Breast Carcinoma to the Skin

Roman Drozdowski, BS, Kristin Torre, MD, Michael Murphy, MD

#112 - Mask-Related Acne in the COVID-19 Pandemic: An Analysis of Twitter Posts and Influencers

Roman Drozdowski, BS, Christian Gronbeck, BA, Hao Feng, MD, MHS

#113 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

April Armstrong; Bruce Strober; Melinda Gooderham; Kim Papp; Richard B Warren; Diamant Thaçi; Peter Foley; Akimichi Morita; John Throup; Sudeep Kundu; Subhashis Banerjee; Andrew Blauvelt, MD

#114 - Selective Inhibition of Tyrosine Kinase 2 (TYK2) With Deucravacitinib Compared With Janus Kinase (JAK) 1–3 Inhibitors

Anjaneya Chimalakonda, PhD; James Burke, PhD*; Lihong Cheng, MS; Ian Catlett, PhD; Aditya Patel, MD, MBA; Jun Shen, PhD; Ihab G. Girgis, PhD; Subhashis Banerjee, MD;
John Throup, PhD

#115 - Utilization of Altmetric and PlumX scores in evaluating the top 100 trending psoriasis articles in social media

Grace Sora Ahn, B.S., Shantelle Griffith, M.S., Jashin J. Wu, M.D.

#116 - Review of apremilast combination therapies in the treatment of moderate-to-severe psoriasis

Mirjana G. Ivanic B.A., Akshitha Thatiparti B.S., Shikha Walia B.S., Wilson Liao M.D., Jashin J. Wu M.D.

#117 - Effect of time delays to Mohs micrographic surgery on surgical outcomes in keratinocyte carcinomas

Briana Halle, BA, Erica Grilletta, MD, Lee Wheless, MD, PhD, and Anna Clayton, MD

#118 - Gender Differences in Hidradenitis Suppurativa

Terri Shih, Justine Seivright, Shanice McKenzie, Christina Harview, Allison Truong, Vivian Shi, Richard Bennett, Jennifer Hsiao

#119 - A 26-year-old man with treatment resistant Yao syndrome

Alexa DeMaio, Gabriella Santa Lucia, Harriet Hinen

#120 - Analysis of efficacy outcomes using ERIVANCE-like methodology in patients with locally advanced basal cell carcinoma

Reinhard Dummer, Aaron S Farberg, Ralf Gutzmer, James Spencer, Felix Kiecker, Alexander Guminski, Kurt Gebauer, Carmen Loquai, Caroline Robert, Dirk Schadendorf, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Michael Migden

#121 - Time to onset of creatine kinase elevation in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Aaron S Farberg, Karl Lewis, Meenal Kheterpal, Kurt Gebauer, Alexander Guminski, Carmen Loquai, Nicholas Squittieri, Ralf Gutzmer

#122 - An Open-Label, Repeat-Dose, Maximum-Use Study to Evaluate the Pharmacokinetics of Sofpironium Bromide Gel, 15% Topically Applied in Subjects with Primary Axillary Hyperhidrosis

Brandon Kirsch, MD, Danielle Armas, MD, Deepak Chadha, MS, MBA, RAC

#123 - 18F-FDG Positron Emission Tomography Computed Tomography (PET/CT) has low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stage II/III melanoma

Zachary J. Jaeger, B.S., Gregory A. Williams, M.A., Joyce C. Mhlanga, M.D., Lynn A. Cornelius, M.D., Ryan C. Fields, M.D., F.A.C.S.

#124 - No Difference in Local Recurrence Rates for Surgical versus Non-surgical Treatment of Penile Squamous Cell Carcinoma In Situ

Katie A. O’Connell, MS, Jacob Thomas, BS, Fadi Murad, MD, Anthony Rossi, MD, Chrysalyne D. Schmults , MD

#125 - Evaluation of Ergonomics Education during Dermatologic Training

Neha Deo, BSc, Sama K. Carley MD.,
Nahid Y. Vidal MD

#126 - Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52 Week results from a randomized trial

Nina Magnolo, MD, Külli Kingo, MD, PhD, Vivian Laquer, MD, John Browning, MD, Adam Reich, MD, PhD, Jacek C. Szepietowski, MD, PhD, Deborah Keefe, MD, Rafal Mazur, MD, Pascal Forrer, PhD, Manmath Patekar, MD

#127 - Readability, Quality, and Timeliness of Urticaria Online Health Resources

Devea R. De, BS, Justine Seivright, BS, Danielle Yee, MD, Jennifer L. Hsiao, MD,
Vivian Y. Shi, MD

#128 - Design of a prospective, multicenter, randomized, evaluator-blinded study to evaluate the efficacy and safety of topical minocycline foam 4% with oral isotretinoin for the treatment of moderate-to-severe acne vulgaris

Edward Lain, MD, MBA; Daniel Carrasco, MD

#129 - Clinical usage data demonstrates appropriate utilization of the prognostic 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (cSCC)

Sarah T Arron, MD, PhD; Ashley Wysong, MD, MS; Alison L Fitzgerald, PhD; Jennifer J Siegel, PhD; Sarah J Kurley, PhD; Matthew S Goldberg, MD; Sherrif F Ibrahim, MD, Phd

#130 - Cardiovascular disease burden in cutaneous lupus erythematosus: A systematic review and meta-analysis

Andraia R Li, BS, Gabriella Santa Lucia, BS, BA, Lara Wine Lee, MD

#131 - Psoriasiform Dermatitis Following Intravenous Immunoglobulin Therapy: A Case Series

India S. Robinson, BA; Tyler J. Willenbrink, MD; Jessica S. Connett, MD; Lara Wine Lee, MD, PhD

#132 - Eosinophils and Melanoma: A Review

India Robinson, B.A., Gabriella Santa Lucia, B.S, B.A, Andraia Li, BS, John Plante, MD, MSCR, Nathaniel Oberholtzer, B.S, Daniel Reuben, M.D., Shikhar Mehrota, Ph. D., Manuel Valdebran, M.D.

#133 - Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from 7 randomized, placebo-controlled studies

Norma P.M. Rubini, PhD, Jonathan I. Silverberg, MD, PhD, MPH, Mario C. Pires, MD, Zhen Chen, PhD, MPH, Jingdong Chao, PhD, Gaëlle Bégo-Le Bagousse, MSc

#134 - Dupilumab Improves Eczema Area and Severity Index Regional Scores Across All Anatomical Regions in Children Aged 6–11 Years with Severe Atopic Dermatitis (AD)

Danielle Marcoux, MD, Michael J. Cork, PhD, Jashin J. Wu, MD, Andreas Wollenberg, MD, Zhen Chen, PhD, MPH, Randy Prescilla, MD, Brad Shumel, MD

#135 - Integration of the 31-gene expression profile test with clinicopathologic features (i31-GEP) for sentinel lymph node positivity risk in patients with cutaneous melanoma

Eric Whitman, MD, Ann Quick, PhD, Brian Martin, PhD, Christine Bailey, MPH, Kyle R. Covington, PhD, Robert Cook, PhD, David Hyams, MD, John Vetto, MD

#136 - Tildrakizumab 100 mg efficacy and safety by metabolic syndrome status in psoriasis: Post hoc analysis of 5-year data from the phase 3 reSURFACE 1 and reSURFACE 2 studies

Anthony P. Fernandez, MD, PhD; Esteban Dauden, MD, PhD; Raquel Rivera, MD; Mark G. Lebwohl, MD; M. Alan Menter, MD; Melinda Gooderham, MD; Kurt Gebauer, MBBS; Yayoi Tada, MD, PhD; Ignasi Pau-Charles, MD; Stephen J. Rozzo, PhD; Nehal N. Mehta, MD

#137 - 5-year efficacy of tildrakizumab 100 and 200 mg in achieving and maintaining PASI 75/90/100 and PGA 0/1 in reSURFACE 1 and 2

Andrew Blauvelt, MD, MBA; Aaron S. Farberg, MD; Rodney Sinclair, MD, MBBS; Sameh Hanna, MD; Akihiko Asahina, MD, PhD; Atsuyuki Igarashi, MD, PhD; Scott Guenthner, MD; Kimberly Eads, MSN; Heather Roebuck, DNP; Stephen J Rozzo, PhD; Lyn Guenther, MD

#138 - Safety of tildrakizumab 100 mg and 200 mg through 5 years of exposure in reSURFACE 1 and reSURFACE 2

George Han, MD, PhD; Pablo Fernández-Peñas, MD, PhD; Lorne Albrecht, MD; Akihiko Asahina, MD, PhD; Atsuyuki Igarashi, MD, PhD; Andrea Nguyen, PA-C, MS; Wendy Cantrell, DNP, CRNP; Jayme Heim, MSN, FNP-BC; Stephen J Rozzo, PhD; Neal Bhatia, MD

#139 - Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials

Kristian Reich, MD, Yukari Okubo, MD, Kenneth Gordon, MD, Andrew Blauvelt, MD, April Armstrong, MD, Dirk De Cuyper, MD, Christopher Cioffi, PhD, Luke Peterson, MS, Mark Lebwohl, MD

#140 - Bimekizumab response maintenance up to 1 year in patients with moderate-to-severe plaque psoriasis: Pooled results from three phase 3 trials

Andrew Blauvelt, MD, Yayoi Tada, MD, Lars Iversen, DMSc, Ulrich Mrowietz, MD, Mark Lebwohl, MD, Maggie Wang, MS, Veerle Vanvoorden, MS, Eva Cullen, PhD, Fabienne Staelens, MD, Kim A. Papp, MD

#141 - Speed of clinical response and improvement in psoriasis with bimekizumab: Pooled results from the multicenter, randomized, double-blinded phase 3 BE VIVID, BE READY and BE SURE trials

Mark Lebwoh, MDl, Philip Hampton, MBBS, PhD, Akimichi Morita, MD, PhD, Kristian Reich, MD, Jo Lambert, MD, PhD, Eva Cullen, PhD, Christopher Cioffi, PhD, Maggie Wang, MS, Cynthia Madden, MD, Richard Langley, MD

#142 - Evaluation of efficacy and tolerance of novel scar gel formulated with traditional silicone and a new biotechnological active ingredient

Virginie Ribet, PharmD, Dylan Bassett, PharmD, Christine Cadeau, MD

#143 - Mayne Pharma_Evaluation of the Safety, Tolerability, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam in Pediatric Patients with Plaque Psoriasis_Hebert et al. 2019

Adelaide Hebert, MD; Debbie Glaab, NP; Rhonda Schreiber, MSRN

#144 - Mayne Pharma_Evaluaiton of Adrenal Suppression Potential of Halobetasol Foam in Adolescent Patients with Plaque Psoriasis_Hebert et al. 2020

Adelaide Hebert, MD; Lawrence Eichenfield, MD; Rhonda Schreiber, MSRN; Debbie Glaab, NP

#145 - Characterizing DRESS Syndrome Recurrence

Ajay N. Sharma BS, Samantha Shwe BS, Vignesh Ravi BS, Melanie Miller MD, Natasha A. Mesinkovska MD, PhD, Nathan W. Rojek MD, Scott Worswick MD

#146 - Dermatologist Perceptions of Teledermatology Implementation & Future Use Post COVID-19

Linda Camaj Deda, Rebecca H Goldberg, Trilokraj Tejasvi, MBBS

#147 - Cross-sectional Study of Alopecia in B-boys and B-girls

Marshall Hall, Henry Lim, Sajid Surve

#148 - Cost-efficient and non-surgical method for treating primary keratinocyte carcinomas with a combination of topical imiquimod, 5-fluorouracil and tretinoin

William J. Nahm, BA; Evangelos V. Badiavas, MD, PhD; Robert S. Kirsner, MD, PhD; Anna J. Nichols, MD, PhD; John Shen, MD

#149 - The treatment of melanoma in situ with telemedicine and a combination of imiquimod, 5-fluorouracil, and tretinoin

William J. Nahm, BA; Eran C. Gwillim, ERAN, MD; Evangelos V. Badiavas, MD, PhD; Anna J. Nichols, MD, PhD; Robert S. Kirsner, MD, PhD; Laurence H. Boggeln, MD; John T. Shen, MD

#150 - Moisture Response Films Versus the Starch Iodine Test for the Detection of Palmar Hyperhidrosis

Waseem Shehadeh MD, Efrat Bar-Ilan MD, Joseph N. Mehrabi MD, Eli Sprecher MD, PhD, and Ofir Artzi MD

#151 - Clinical Considerations Associated with Intra-Oral Recurrent Herpes That Dermatologists Should Consider

Alhanouf Bin Dakhil, MD

#152 - Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry

Benjamin Lockshin, MD; Ryan W. Harrison, MS; Robert R. McLean, DSc, MPH; Margaux M. Crabtree, MPH; Bruce W. Konicek, MS; Baojin Zhu, PhD; William N. Malatestinic, Pharm D, MBA; Bilal Atiya, PharmD; Mwangi J. Murage, PhD, MPH; Russel Burge, PhD

#153 - Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-A

Abel Jarell, MD; Stacy Smith, MD; Gaia Gallo, MD; Lisa Renda, RN, MSN; Russel Burge, PhD; Baojin Zhu, PhD; Jiaying Guo, MS; Emily Blue, PhD; David Rosmarin, MD

#154 - Crosstalk between HIF-1α and SIRT-1 is bolstered by the natural ingredient bakuchiol but not retinol

Hemali Gunt, PhD; Manpreet Randhawa, PhD; Krzysztof Bojanowski, PhD; Ratan Chaudhuri, PhD

#155 - Synergistic blend of green tea and lotus protects against blue light-induced free radicals

Hemali Gunt, PhD; Stenley Levy, MD

#156 - The risk of COVID-19 in patients with atopic dermatitis

Jashin J. Wu, M.D., Amylee Martin, B.S., Jeffrey Liu, B.S., Akshitha Thatiparthi, B.S.

#157 - Association between psoriasis and rheumatoid arthritis in a nationally representative US population

Amylee Martin, B.S., Akshitha Thatiparthi, B.S., Jeffrey Liu, B.S., Jashin J. Wu, M.D.

#158 - Application of nailfold capillaroscopy in viral infections: A systematic review

Andraia Li, BS, Connor Burke, BS, Lara Wine Lee, MD, PhD

#159 - Follicular Keratosis of the Face in Pediatric Skin of Color Patients

Karina Grullon BS, Christopher Shea MD, Arlene Ruiz De Luzuriaga MD MPH MBA, Sarah L. Stein MD, Adena E. Rosenblatt MD PhD

#160 - Prognostic Biomarkers in Melanoma: Tailoring Treatments to the Patient

Albert G. Wu, MS; Carl V. Hamby, PhD, Bijan Safai, MD

#161 - Analyzing Patient Effectiveness Ratings to Stratify Pachyonychia Congenita Treatments

Albert G. Wu MS; Shari R. Lipner M.D. Ph.D.2

#162 - New Sunscreens on the Block: Evaluation of the Online Sunscreen Market in the United States

Jennifer J. Su, BS, Jordan M. Ward, MD, June Y. Moon, BS, Omkar N. Mayur, BS, Loretta S. Davis, MD

#163 - Photo-distributed Toxic Epidermal Necrolysis in A Young Female on Lamotrigine: A Case Report

Joshua Horeczko, BA; Helena Pasieka, MD

#164 - Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active Psoriatic Arthritis in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Philip J Mease, MD, Atul Deodhar, MD, Désirée van der Heijde, MD, Frank Behrens, MD, Alan J Kivitz, MD, Thomas Lehman, PharmD, Lan Wei, PhD, Marleen Nys, RPh, Subhashis Banerjee, MD, Miroslawa Nowak, MD

#165 - Current state of machine learning for non-melanoma skin cancer

Ajay Sharma, MD, Samantha, Shwe, BS, Natasha Atanaskova Mesinkovska, MD, PhD

#166 - Safety and efficacy of JAK inhibitors in alopecia areata, alopecia totalis, and alopecia universalis in the pediatric population: A systematic review and meta-analysis

Meera H. Patel BS, Caitlin M. Brumfiel MS, Brittany E. Yee MD, Amanda Marsch MD

#167 - Real-World Effectiveness of Systemic Therapies for Atopic Dermatitis (AD) in the United States: Analysis of a Retrospective Claims Database

Marco DiBonaventura, Marie-Helene Lafeuille, Bruno Edmond, Mei Sheng Duh, Iman Fakih, Natalie Yin, Daniela Myers, Calire Feeney, Joseph C. Cappelleri, Jashin J. Wu, MD

#168 - Efficacy and Safety of Abrocitinib as Monotherapy or in Combination With Topical Therapy: Results From Four Randomized Clinical Trials

Melinda J. Gooderham, MD, Andrew Blauvelt, MD, Robert Bissonnette, MD, Pinaki Biswas, PhD, Gary L. Chan, PharmD, Claire Feeney, MD, Mark Levenberg, DO, Melissa Watkins, PhD, Hernan Valdez, MD

#169 - Crowdfunding for Cutaneous Oncological Surgery

Kristina Lim, DO, Marc Mitton, DO, Payvand Kamrani, DO, Olivia Dahlgren,
Cynthia Bartus, MD

#170 - Roflumilast cream in chronic plaque psoriasis patients: Efficacy and safety from DERMIS-1 and DERMIS-2

Mark Lebwohl MD, Leon Kircik MD, Angela Moore MD, Linda Stein Gold MD, Zoe Draelos MD, Melinda Gooderham MD, Kim Papp MD, Jerry Bagel MD, Neal Bhatia MD, James Del Rosso MD, Laura Ferris MD, Lawrence Green MD, Adelaide Hebert MD, Terry Jones MD, Steven Kempers, David Pariser, Patrick Burnett, Paul Yamauchi, Matthew Zirwas, Robert C. Higham, Lynn Navale, David Berk

#171 - Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-blind, Vehicle-controlled Phase 2b Study

Leon Kircik MD, Angela Moore MD, Neal Bhatia MD, Alim Devani MD, Zoe Draelos MD, Janet DuBois MD, Melinda Gooderham MD, Steven Kempers MD, Edward Lain MD, Mark Lee MD, Dedee Murrell MD, Kim Papp MD, David Pariser MD, Rodney Sinclair MD, Matthew Zirwas MD, Patrick Burnett, Robert C. Higham, Lynn Navale, David Berk

#172 - Long-term safety and efficacy of roflumilast cream 0.3% in adult patients with chronic plaque psoriasis: results from a 52-week, phase 2b open-label study

Linda Stein Gold MD, Melinda Gooderham MD, Kim Papp MD, Laura Ferris MD, Mark Lebwohl MD, David Adam MD, Javier Alonso-Llamazares MD, H Chih-ho Hong MD, Steven Kempers MD, Leon Kircik MD, Wei Jing Loo MD, Walter Nahm MD, Daniel Stewart MD, Matthew Zirwas, MD, Patrick Burnett, Robert C. Higham, Lynn Navale, David R. Berk

#173 - Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Randomized, Double-blind, Vehicle-controlled Phase 2 Study

Matthew Zirwas MD, Zoe Draelos MD, Janet DuBois MD, Leon Kircik MD, Angela Moore MD, Linda Stein Gold MD, Patrick Burnett MD, Robert Higham NP, Lynn Navale MS, David Berk MD

#174 - Validation of the CD8+/CD68+ Cell Ratio as a Prognostic Biomarker in Stage II-II Melanoma

A. Reza Djavid, BA, Benjamin T. Fullerton, BA, Samuel W. Wang, BA, Meghan S. Drastal, BS, Luke W. Barker, BS, Robyn D. Gartrell, MD, Bethany R. Rohr, MD, Tammie C. Ferringer, MD, Yvonne M. Saenger, MD

#175 - Hidradenitis Suppurativa Specialty Clinics and Instagram Usage

Lindsey Ayanruoh, MBS; Joyce H. Park, M.D.

#176 - Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis (AD) From the Phase 2 and Phase 3 Clinical Trial Program

Eric L. Simpson, MD, Jonathan I. Silverberg, MD, Audrey Nosbaum, MD, Kevin Winthrop, MD, Emma Guttman-Yassky, MD, Karin M. Hoffmeister, MD, Min Zhang, PhD, Saleem A. Farooqui, MBBS, Susan Johnson, MD, Andrew J. Thorpe, PhD, Ricardo Rojo, MD

#177 - Exacerbation of chronic inflammatory skin disease after COVID-19 vaccine: a report of 2 cases and review of the literature

Cassandra Drew, BS, Leah Shin, BA, Lulu Wong, MD, Nancy Anderson, MD

#178 - Assessing and Optimizing Readability of Dermatology Patient Education Materials (PEMs)

Ahdarsh Vallabhaneni, BS Peter N. Eskander, BS Kari Martin, MD Kimberly Eisenstein, MD Jonathan Dyer, MD

#179 - Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study

Vivian Shi; Tina Bhutani; Mette Deleuran; Luz Fonacier; Stephen Shumack; Fan Zhang; Michael C. Cameron; Gary Chan; Hernan Valdez; Natalie Yin

#180 - Abrocitinib Induction, Randomized Withdrawal, and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial

Walter Gubelin, Eric L. Simpson, Andrew Blauvelt, Ryszard Galus, Chia-Yu Chu, Marco DiBonaventura, Heman Valdez, Tahira Khan, Pinaki Biswas, Michael C. Cameron, Ricardo Rojo

#181 - Examining psoriatic lesions using the Mindera dermal biomarker patch

Tobin J. Dickerson, PhD*, Byung-In Lee, PhD, Paul Montgomery III MS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD Mindera Corporation, San Diego, CA 92123

#182 - A rare presentation of Gorlin syndrome in a patient of African ancestry

Stephanie Chan B.S., Nicole Negbenebor, M.D., Oliver Wisco D.O.

Back to Symposium Archives